OUR PIPELINE

Our Pipeline Is Designed To Address Critical Unmet Needs

Our Highlights to Date​

Lead Development Programs​

  • FDA regulatory submissions (pre-IND) for VRON-0200 HBV and VRON-0100 HPV programs ​
  • Lead VRON-0200 HBV program
    • Phase 1b scheduled to begin Q4 2022 (~3.5 years from de novo program initiation to clinic)​
    • “Best of the International Liver Congress” at EASL 20211; oral presentation at APASL 2022​2
    • Significant and clear differentiation in this large unmet medical need disease indication​

VRON-0200: Treatment of HBV Infection

The T Cell Platform for Multi-Modal Therapies & Functional Cure

VRON-0200 is designed to address a global high unmet medical need for chronic HBV infection. VRON-0200 combines a genetically encoded checkpoint modifier along with selected and optimized antigens of choice and delivered by ChiVax™, our heterologous chimpanzee adenoviral vectors that promotes potent, prolonged, and broad CD8+ T cell responses.

Platform Technologies​

  • Preclinical studies with the lead checkpoint modifier: HBV, HPV, melanoma, influenza virus, HIV and COVID-191,3–7  ​
  • Clinical studies: NIH sponsored Phase 1 HIV Prevention trial (South Africa) using our vectors8
  • Future global health and pandemic needs: The ChiVax™ platform can quickly respond and adapt to help address current and future global public health pandemic and other infectious diseases needs

CD, cluster of differentiation; FDA, Food and Drug Administration; gCPM, genetically encoded checkpoint modifier; gD, glycoprotein D; HBV, hepatitis B virus; HIV, human immunodeficiency virus; HPV, human papillomavirus; IND, investigational new drug; MOA, mechanism of action; NIH, National Institutes of Health.

  1. Hasanpourghadi M, et al. EASL 2021:Abstract OS-2478.
  2. Hasanpourghadi M, et al. APASL 2022:Abstract OS-0685.
  3. Xiang Z, et al. ASCO-SITC Clinical Immuno-Oncology Symposium 2020:Abstract 71.
  4. Zhang Y and Ertl HCJ. J Immunol. 2014;193:1836–46.
  5. Dawany N, et al. Aging (Albany NY). 2016;8:3727–97.
  6. Tuyishime S, et al. EBioMedicine. 2018;31:25–35.
  7. Novikov M, et al. BioRxiv. Published online January 1, 2022. DOI:10.1101/2022.02.23.481620.
  8. HIV Vaccine Trials Network (HVTN)-139 trial, South African Medical Research Council.